Pulse Biosciences Q2: $100M Cash Buys Time, but Atrial Fibrillation Data Will Decide the Stock

Q2 numbers missed, but investors kept their eyes on the AF trial

The market treated the quarter's income statement miss as secondary to clinical progress. Pulse reported an adjusted loss of $0.36 a share versus $0.28 expected, and revenue of $400,000 against a $600,000 forecast. That pointed to weak near-term commercial output and higher spending. But investors also saw cash and cash equivalents totaled $101.6 million, which meant the company had time to reach its key trial milestones without an immediate cash crisis.

What the market was really pricing

Vybrance disposable sales did improve sequentially to $434,000, but that is still small relative to Pulse's spending needs. The bigger issue was not the quarter itself; it was whether the company could use its cash runway to reach a meaningful atrial fibrillation readout. If enrollment and data timing stay on schedule, investors can start pricing a later commercial outcome well before current sales become material. If timing slips, however, the cash cushion becomes less reassuring because additional financing could dilute existing holders.

Pulse is leaning harder into cardiology because that is where the main upside sits

Pulse has now strategic prioritization of the nPulse Cardiac Catheter System after presenting what management described as landmark clinical data. The pivotal NANOPULSE-AF study has enrolled more than 82 patients, and management expects enrollment to finish in early Q4 2026, which it has called three months ahead of schedule. That is why the stock remains an event-driven story: earlier completion can pull later regulatory and commercial milestones closer, and Pulse already has a stronger cash position to help it get there.

The feasibility data are part of that appeal. Pulse reported 100% procedural success by Holter monitor at six months and 96% at 12 months in its first-in-human European feasibility set, along with a 90% Kaplan-Meier estimate of freedom from recurrent atrial arrhythmias at one year. Feasibility studies are not definitive, but they do suggest the treatment effect could be durable enough to matter clinically. A reported 1.7% serious adverse event rate also supports the idea that safety may be manageable within this early evidence set.

Workflow efficiency may matter just as much as efficacy. Multiple sites have been performing five to seven cases per day, with ablation times of about seven to eight minutes. In electrophysiology, that kind of efficiency can help persuade labs to adopt a new system even while the pivotal evidence is still maturing.

Pulse is also advancing thyroid and surgical programs alongside cardiac, which keeps the broader nsPFA platform narrative alive. That does not reduce the importance of cardiac success, but it does make the company look more like a platform than a single-trial story. The existing dermatology business still follows a utilization-based revenue model, so it can provide some early cash flow, but it is not the main source of upside. For now, cardiology still drives the valuation.

ATM financing extended the runway, but dilution remains a real risk

Cash helped Pulse fund the path to its cardiac milestones, but capital raised through equity is not free. During Q2, the company raised $46.8 million in net proceeds through an at-the-market program. After quarter end, it raised another $10.7 million in net proceeds through the ATM, plus $1.8 million in gross proceeds from warrant exercises. The financing story gets some support from the fact that roughly approximately $13.3 million came from the co-chairmen, which suggests insider confidence. Pulse has also Announces Planned Redemption of Warrants, which may help reduce some of the longer-term dilution concern.

Why financing can still limit upside

The positive reading is simple: the ATM gave Pulse room to reach the early Q4 enrollment target and the next wave of regulatory milestones. The cautious reading is that repeated ATM draws can still increase shares outstanding if the company keeps relying on equity rather than commercial cash flow or other financing structures. That does not have to destroy upside, but it can cap valuation even if the science works out.

What matters most over the next one to two quarters

The stock still looks like an execution story centered on timing, data, and financing discipline.

The bull case improves if Pulse keeps early Q4 enrollment completion, makes progress toward a CE Mark submission in the second half of 2026, and avoids another balance-sheet stretch despite recent financing activity. That would support the view that the cash base is a runway to proof points rather than a temporary fix.

Watch for these warning signs instead:

• enrollment slows and early Q4 completion no longer looks credible
• operating spending rises without a matching advance in trial milestones
• the commercial base stays so small that it does little to change the story

If the atrial fibrillation data disappoint, the main reason for the stock's premium likely disappears. Until then, Pulse still looks more like a clinical execution trade than a proven business.